Candel Therapeutics Inc (CADL)

$10.07 +0.06 (0.60%)
Market Cap 733.43M
Revenue (ttm) 0.00
Net Income (ttm) -38.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.34
Volume 878,200
Avg Vol 1,728,728
Day's Range N/A - N/A
Shares Out 73.27M
Stochastic %K 80%
Beta -0.52
Analysts Strong Sell
Price Target $20.00

Company Profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic,...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 916 5445
Address:
117 Kendrick Street, Suite 450, Needham, United States
jowzakiki
jowzakiki Aug. 4 at 3:06 PM
$CADL We expect it to break through 10.50 in order to continue rising to 11.
0 · Reply
stu4
stu4 Aug. 4 at 2:59 PM
$CADL Makes sense ..NO VOLUME..it’s above. $10 Hahahahahaha
0 · Reply
bad_at_stocks
bad_at_stocks Aug. 4 at 2:52 PM
$CADL there are funds who are not allowed to buy stock under $10, so you can see why shorty is nervous
0 · Reply
chrundel
chrundel Aug. 4 at 2:50 PM
$CADL watching the order book is interesting. No one meaningful selling... a few shares here and there, at times the spread is super wide. Inventory is likely pretty low. Soft breeze could send this up 50 cents.
0 · Reply
badprecog
badprecog Aug. 4 at 2:49 PM
$CADL A rolling filing makes sense because it increases the odds of getting priority review.
0 · Reply
haha1978
haha1978 Aug. 4 at 2:47 PM
$CADL Also look for the CEO to surprise the market with an early BLA filing. Thats one way to get this moving. Enjoy the ride. Easy $20 by EOY.
0 · Reply
haha1978
haha1978 Aug. 4 at 2:45 PM
$CADL This market cap is a joke and is way to low. MACD crossing over tomorrow so enjoy the run to 13 to 14. This should be a 1.5 billion market cap today minimum.
1 · Reply
Greyhound9
Greyhound9 Aug. 4 at 2:36 PM
$CADL NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that an abstract was accepted for poster presentation at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place September 26-30, 2026, in Boston, MA. For the new people here, good to know.
0 · Reply
Greyhound9
Greyhound9 Aug. 4 at 2:31 PM
$CADL Ask Yahoo Scout News headlines Updated 5m ago Candel Therapeutics is making strides with its lead therapy, Aglatimagene Besadenovec, showing positive Phase 3 results and preparing for upcoming presentations and conferences. The company recently announced inducement grants and plans to present new data at major medical conferences, reflecting strong momentum in its clinical development efforts. Upcoming Presentations: Candel will present at the Canaccord Genuity’s 46th Annual Growth Conference on August 12, 2026, focusing on its clinical advancements and market strategies. Retail Investor Sentiment: Retail sentiment remains bullish, with Candel's stock showing significant gains, attributed to positive trial results and upcoming milestones.
0 · Reply
chrundel
chrundel Aug. 4 at 2:23 PM
$CADL they’re hard at work this morning, yawl! Haha. Pops up, gets stuffed back down. Pops up, gets stuffed back down.
3 · Reply
Latest News on CADL
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 3, 2026, 4:05 PM EDT - 19 hours ago

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

Aug 3, 2026, 8:05 AM EDT - 1 day ago

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

Candel Therapeutics to Present at Canaccord Genuity's 46th Annual Growth Conference in Boston

Jul 29, 2026, 8:05 AM EDT - 6 days ago

Candel Therapeutics to Present at Canaccord Genuity's 46th Annual Growth Conference in Boston

Candel Therapeutics initiated with a Buy at Stifel

2026-07-13T09:40:23.000Z - 22 days ago

Candel Therapeutics initiated with a Buy at Stifel

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 8, 2026, 4:05 PM EDT - 26 days ago

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics Slides: Corporate presentation

Jul 7, 2026, 7:00 AM EDT - 4 weeks ago

Candel Therapeutics Slides: Corporate presentation

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2026, 4:05 PM EDT - 4 weeks ago

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Jun 30, 2026, 8:05 AM EDT - 5 weeks ago

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

Jun 25, 2026, 8:05 AM EDT - 5 weeks ago

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

Candel Therapeutics Transcript: AGM 2026

Jun 23, 2026, 10:00 AM EDT - 6 weeks ago

Candel Therapeutics Transcript: AGM 2026

Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 5:30 PM EDT - 2 months ago

Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene

2026-06-02T14:27:23.000Z - 2 months ago

Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Jun 2, 2026, 8:05 AM EDT - 2 months ago

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Candel Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum

May 20, 2026, 10:00 AM EDT - 2 months ago

Candel Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum

Candel Therapeutics price target raised to $9 from $7 at BofA

2026-05-18T19:30:09.000Z - 2 months ago

Candel Therapeutics price target raised to $9 from $7 at BofA

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting

May 15, 2026, 4:05 PM EDT - 2 months ago

Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting

Candel Therapeutics Transcript: Study result

May 15, 2026, 1:00 PM EDT - 2 months ago

Candel Therapeutics Transcript: Study result

Candel Therapeutics Slides: Study result

May 15, 2026, 1:00 PM EDT - 2 months ago

Candel Therapeutics Slides: Study result

Candel Therapeutics Press release: Study result

May 15, 2026, 1:00 PM EDT - 2 months ago

Candel Therapeutics Press release: Study result

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 14, 2026, 8:05 AM EDT - 2 months ago

Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Candel Therapeutics Earnings release: Q1 2026

May 14, 2026, 8:00 AM EDT - 2 months ago

Candel Therapeutics Earnings release: Q1 2026

Candel Therapeutics Quarterly report: Q1 2026

May 14, 2026, 8:00 AM EDT - 2 months ago

Candel Therapeutics Quarterly report: Q1 2026

Candel Therapeutics Slides: Corporate presentation

May 14, 2026, 7:00 AM EDT - 2 months ago

Candel Therapeutics Slides: Corporate presentation

Candel Therapeutics to Present at Upcoming Investor Conferences

May 13, 2026, 8:05 AM EDT - 2 months ago

Candel Therapeutics to Present at Upcoming Investor Conferences

Candel Therapeutics Slides: Corporate presentation

May 13, 2026, 7:00 AM EDT - 2 months ago

Candel Therapeutics Slides: Corporate presentation

Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

May 4, 2026, 8:05 AM EDT - 3 months ago

Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

Apr 29, 2026, 8:05 AM EDT - 3 months ago

Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

Candel Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Candel Therapeutics Proxy statement: Proxy filing

Candel Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Candel Therapeutics Proxy statement: Proxy filing

Candel Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-04-20T10:42:20.000Z - 3 months ago

Candel Therapeutics initiated with an Overweight at Cantor Fitzgerald

Candel Therapeutics Slides: Corporate presentation

Apr 14, 2026, 7:00 AM EDT - 4 months ago

Candel Therapeutics Slides: Corporate presentation

Candel Therapeutics price target raised to $26 from $22 at Citi

2026-03-18T10:22:07.000Z - 4 months ago

Candel Therapeutics price target raised to $26 from $22 at Citi

Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC

2026-03-17T12:22:09.000Z - 5 months ago

Candel Therapeutics’ aglatimagene shows extended long-term survival in NSCLC

Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Mar 17, 2026, 8:05 AM EDT - 5 months ago

Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Candel Therapeutics Slides: Corporate presentation

Mar 17, 2026, 7:00 AM EDT - 5 months ago

Candel Therapeutics Slides: Corporate presentation

Candel Therapeutics price target lowered to $22 from $24 at Citi

2026-03-13T10:45:12.000Z - 5 months ago

Candel Therapeutics price target lowered to $22 from $24 at Citi

Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year

2026-03-12T12:11:41.000Z - 5 months ago

Candel Therapeutics reports Q4 EPS (54c) vs. (40c) last year

Candel Therapeutics sees cash runway into 1Q28

2026-03-12T12:11:01.000Z - 5 months ago

Candel Therapeutics sees cash runway into 1Q28

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Mar 12, 2026, 8:05 AM EDT - 5 months ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Candel Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 5 months ago

Candel Therapeutics Earnings release: Q4 2025

Candel Therapeutics Annual report: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 5 months ago

Candel Therapeutics Annual report: Q4 2025

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Mar 9, 2026, 8:05 AM EDT - 5 months ago

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Candel Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:50 AM EST - 5 months ago

Candel Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston

Feb 24, 2026, 8:05 AM EST - 5 months ago

Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston

Candel Therapeutics 18.3M share Spot Secondary priced at $5.45

2026-02-20T03:25:29.000Z - 5 months ago

Candel Therapeutics 18.3M share Spot Secondary priced at $5.45

Candel Therapeutics 18.3M share Spot Secondary priced at $5.45

2026-02-20T03:25:12.000Z - 5 months ago

Candel Therapeutics 18.3M share Spot Secondary priced at $5.45

Candel Therapeutics Announces Pricing of Public Offering

Feb 19, 2026, 9:40 PM EST - 5 months ago

Candel Therapeutics Announces Pricing of Public Offering

Candel Therapeutics announces $100M royalty funding agreement

2026-02-19T22:10:17.000Z - 5 months ago

Candel Therapeutics announces $100M royalty funding agreement

Candel Therapeutics announces $100M common stock offering

2026-02-19T21:13:42.000Z - 5 months ago

Candel Therapeutics announces $100M common stock offering

Candel Therapeutics Announces Proposed $100 Million Public Offering

Feb 19, 2026, 4:05 PM EST - 5 months ago

Candel Therapeutics Announces Proposed $100 Million Public Offering

Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Feb 19, 2026, 4:01 PM EST - 5 months ago

Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

Feb 11, 2026, 8:05 AM EST - 6 months ago

Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

Candel Therapeutics Slides: Corporate Presentation

Dec 10, 2025, 7:00 AM EST - 8 months ago

Candel Therapeutics Slides: Corporate Presentation

Candel Therapeutics Transcript: R&D Day 2025

Dec 5, 2025, 11:00 AM EST - 8 months ago

Candel Therapeutics Transcript: R&D Day 2025

Candel Therapeutics Press release: FY 2025

Dec 5, 2025, 11:00 AM EST - 8 months ago

Candel Therapeutics Press release: FY 2025

Candel Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 3:00 AM EST - 9 months ago

Candel Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

Nov 17, 2025, 4:05 PM EST - 9 months ago

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

Candel Therapeutics price target lowered to $24 from $25 at Citi

2025-11-14T11:40:57.000Z - 9 months ago

Candel Therapeutics price target lowered to $24 from $25 at Citi

Candel Therapeutics reports Q3 EPS (21c) vs (33c) last year

2025-11-13T13:31:40.000Z - 9 months ago

Candel Therapeutics reports Q3 EPS (21c) vs (33c) last year

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 13, 2025, 8:25 AM EST - 9 months ago

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

TRIN

Candel Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

Candel Therapeutics Quarterly report: Q3 2025

Candel Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

Candel Therapeutics Earnings release: Q3 2025

Candel Therapeutics Slides: Corporate Presentation

Nov 12, 2025, 7:00 AM EST - 9 months ago

Candel Therapeutics Slides: Corporate Presentation

Candel Therapeutics announces it will deliver three presentations at SITC

2025-11-04T14:10:59.000Z - 9 months ago

Candel Therapeutics announces it will deliver three presentations at SITC

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

Nov 4, 2025, 9:00 AM EST - 9 months ago

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

Nov 3, 2025, 8:05 AM EST - 9 months ago

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

Candel initiated with an Overweight at Stephens on differentiated pipeline

2025-10-28T11:21:24.000Z - 10 months ago

Candel initiated with an Overweight at Stephens on differentiated pipeline

Candel Therapeutics initiated with an Overweight at Stephens

2025-10-27T20:35:14.000Z - 10 months ago

Candel Therapeutics initiated with an Overweight at Stephens

Candel Therapeutics initiated with an Outperform at LifeSci Capital

2025-10-21T10:40:56.000Z - 10 months ago

Candel Therapeutics initiated with an Outperform at LifeSci Capital

Candel Therapeutics appoints Pulendran to Candel’s RAB

2025-10-16T12:20:35.000Z - 10 months ago

Candel Therapeutics appoints Pulendran to Candel’s RAB

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

Oct 16, 2025, 8:05 AM EDT - 10 months ago

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

Oct 14, 2025, 8:10 AM EDT - 10 months ago

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

Oct 14, 2025, 8:10 AM EDT - 10 months ago

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

TRIN

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

Oct 14, 2025, 8:05 AM EDT - 10 months ago

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Oct 3, 2025, 9:05 AM EDT - 10 months ago

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 29, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 17, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Candel Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 7:00 AM EDT - 11 months ago

Candel Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Candel Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 8:00 AM EDT - 11 months ago

Candel Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Candel Therapeutics Transcript: Citi's Biopharma Back to School Conference

Sep 3, 2025, 9:00 AM EDT - 11 months ago

Candel Therapeutics Transcript: Citi's Biopharma Back to School Conference

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.

Sep 2, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 28, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 14, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Candel Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Quarterly report: Q2 2025

Candel Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Earnings release: Q2 2025

Candel Therapeutics Registration statement: Registration Filing

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Registration statement: Registration Filing

Candel Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 13, 2025, 2:00 PM EDT - 1 year ago

Candel Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 30, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Jul 24, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

Jul 9, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

Jun 24, 2025, 9:05 AM EDT - 1 year ago

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

Jun 23, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Jun 6, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 11:40 AM EDT - 1 year ago

Candel Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

May 28, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

May 27, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

May 22, 2025, 5:05 PM EDT - 1 year ago

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Candel Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 7:20 PM EDT - 1 year ago

Candel Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 13, 2025, 8:05 AM EDT - 1 year ago

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Candel Therapeutics Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Quarterly report: Q1 2025

Candel Therapeutics Earnings release: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Earnings release: Q1 2025

Candel Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Proxy statement: Proxy Filing

Candel Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Proxy statement: Proxy Filing

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Apr 1, 2025, 8:01 AM EDT - 1 year ago

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D.

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D.

jowzakiki
jowzakiki Aug. 4 at 3:06 PM
$CADL We expect it to break through 10.50 in order to continue rising to 11.
0 · Reply
stu4
stu4 Aug. 4 at 2:59 PM
$CADL Makes sense ..NO VOLUME..it’s above. $10 Hahahahahaha
0 · Reply
bad_at_stocks
bad_at_stocks Aug. 4 at 2:52 PM
$CADL there are funds who are not allowed to buy stock under $10, so you can see why shorty is nervous
0 · Reply
chrundel
chrundel Aug. 4 at 2:50 PM
$CADL watching the order book is interesting. No one meaningful selling... a few shares here and there, at times the spread is super wide. Inventory is likely pretty low. Soft breeze could send this up 50 cents.
0 · Reply
badprecog
badprecog Aug. 4 at 2:49 PM
$CADL A rolling filing makes sense because it increases the odds of getting priority review.
0 · Reply
haha1978
haha1978 Aug. 4 at 2:47 PM
$CADL Also look for the CEO to surprise the market with an early BLA filing. Thats one way to get this moving. Enjoy the ride. Easy $20 by EOY.
0 · Reply
haha1978
haha1978 Aug. 4 at 2:45 PM
$CADL This market cap is a joke and is way to low. MACD crossing over tomorrow so enjoy the run to 13 to 14. This should be a 1.5 billion market cap today minimum.
1 · Reply
Greyhound9
Greyhound9 Aug. 4 at 2:36 PM
$CADL NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that an abstract was accepted for poster presentation at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place September 26-30, 2026, in Boston, MA. For the new people here, good to know.
0 · Reply
Greyhound9
Greyhound9 Aug. 4 at 2:31 PM
$CADL Ask Yahoo Scout News headlines Updated 5m ago Candel Therapeutics is making strides with its lead therapy, Aglatimagene Besadenovec, showing positive Phase 3 results and preparing for upcoming presentations and conferences. The company recently announced inducement grants and plans to present new data at major medical conferences, reflecting strong momentum in its clinical development efforts. Upcoming Presentations: Candel will present at the Canaccord Genuity’s 46th Annual Growth Conference on August 12, 2026, focusing on its clinical advancements and market strategies. Retail Investor Sentiment: Retail sentiment remains bullish, with Candel's stock showing significant gains, attributed to positive trial results and upcoming milestones.
0 · Reply
chrundel
chrundel Aug. 4 at 2:23 PM
$CADL they’re hard at work this morning, yawl! Haha. Pops up, gets stuffed back down. Pops up, gets stuffed back down.
3 · Reply
Musky49
Musky49 Aug. 4 at 2:22 PM
$CADL Great post here KJ
1 · Reply
Drcando
Drcando Aug. 4 at 2:10 PM
$CADL Strong like Bull KWYO Monster stock IMO
1 · Reply
Greyhound9
Greyhound9 Aug. 4 at 2:09 PM
$CADL Anyone still saying this company is going to $4 needs to be institutionalized. 🤭 I also think that in 6-12 people will say "I wish I had" and be done, then they'll be waaaaaaaaaay too late. 🤪
0 · Reply
CO145
CO145 Aug. 4 at 2:08 PM
$CADL Once it achieves the first Billion, the second and third is always much easier, particularly when the TAM is so large.
1 · Reply
badprecog
badprecog Aug. 4 at 1:58 PM
$CADL In about 6 months people will be saying that was the most obvious pick of all time.
0 · Reply
ilikemoney247
ilikemoney247 Aug. 4 at 1:45 PM
$CADL lets keep this double digit energy up!
0 · Reply
jowzakiki
jowzakiki Aug. 4 at 1:37 PM
$CADL
0 · Reply
sma1laxe
sma1laxe Aug. 4 at 1:36 PM
$CADL 🔭
0 · Reply
Musky49
Musky49 Aug. 4 at 1:34 PM
$CADL 💪✅👊🎯
0 · Reply
CO145
CO145 Aug. 4 at 1:33 PM
$CADL $10 is insignificant. $13.50 is significant.
0 · Reply
MadeMaid
MadeMaid Aug. 4 at 1:18 PM
$CADL so your telling me Ibrx 200 million a year revenue is at 7 billion cap. If this gets approved with even some dilution we are golden.
2 · Reply
Deeconomics
Deeconomics Aug. 4 at 10:18 AM
$CADL CAN-2409 less severe side effects and superior DFS stand out more each time a existing blockbuster prostate cancer drug's side effects are looked at. Novartis' Pluvicto (Not a direct competitor to CAN-2409) is mentioned for potential $5 billion peak sales due to FDA expanded use approval that could nearly double patients that may use it. Regarding recurrence and side effects, CAN-2409 demonstrates a major impact on reducing local recurrence—showing a 30% to 39% improvement in disease-free survival when added to radiotherapy—and boasts a notably mild, less harsh toxicity profile consisting primarily of temporary flu-like symptoms compared to the more severe bone marrow and renal toxicities associated with systemic radiation therapies like Pluvicto. https://www.fiercepharma.com/pharma/novartis-rlt-pluvicto-leaps-ahead-earlier-manifestation-prostate-cancer
3 · Reply